Previous 10 | Next 10 |
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce tha...
Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting the price and size of the public offering it announced earlier this week. Accordin...
- To date, CYB003 has demonstrated a robust psychedelic response and a favorable safety and tolerability profile at doses of up to 12mg - - Phase 2 topline efficacy data expected in Q3/Q4 2023 - Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the &...
2023-08-01 10:31:36 ET Cybin ( NYSE: CYBN ) has priced its overnight marketed public offering to raise US$8.25 million, the company said Tuesday. The company said it is offering 24,264,706 units at US$0.34 apiece. The offer price represents a 15% discount to the stock's cl...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today the pricin...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce tha...
Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be represented at the upcoming 43rd annual Canaccord Genuity Growth Conference. The c...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Do...
2023-07-26 08:45:24 ET Palm Beach, FL – July 26, 2023 – FinancialNewsMedia.com News Commentary – Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise in the coming yea...
-Collaboration with Worldwide Clinical Trials provides Cybin with access to a contract research organization with substantial experience supporting multinational psychedelic clinical trials - - Cybin expects to report Phase 2 topline efficacy data for CYB003 in major depressive disorder i...
News, Short Squeeze, Breakout and More Instantly...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting “a swell” of insider purchases followi...
Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update on progress made in fiscal 2024 ending on March 31st. In its presser , Cybin highlighted k...